• Mirum outlined new clinical data for its rare liver disease pipeline ahead of presentations at the EASL International Liver Congress 2026 in Barcelona on May 27-30.
• Late-breaking Phase 2b VISTAS results for volixibat in primary sclerosing cholangitis are scheduled for oral presentation on May 30, with the study described as showing rapid, sustained relief of itching symptoms.
• Phase 2b AZURE-1 data for brelovitug in chronic hepatitis D are set for late-breaking poster presentation on May 29, with results described as supporting both efficacy and safety.
• Additional data on LIVMARLI (maralixibat) in progressive familial intrahepatic cholestasis will be presented on May 30, including analyses positioned as supporting longer-term outcomes in treated patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605210805BIZWIRE_USPR_____20260521_BW728786) on May 21, 2026, and is solely responsible for the information contained therein.